Small Business Innovation Research (SBIR) to Develop New Methods and Technologies for Assessment of Risk and for Early Diagnosis and Prognosis of Type 1 Diabetes (T1D)
May 2021 Council
Point(s) of Contact
Guillermo A. Arreaza-Rubín, M.D.
Early identification of type 1 diabetes (T1D) risk and the onset of autoimmunity provides the basis for a variety of major ongoing studies seeking to prevent or delay the disease. Ongoing research on the natural history of the development of T1D in at risk neonates has shown that early identification of those at risk can foster early diagnosis of T1D and avoid life-threatening diabetic ketoacidosis (DKA). It is estimated that 40-60% of people with T1D in the US still present with DKA at the time of the diagnosis. The goal of this initiative is to develop innovative technologies/biomarkers that may advance progress towards early detection and follow-up of individuals at risk of developing T1D to avoid acute complications at diagnosis and to allow earlier interventions to prevent and/or delay clinical manifestations and long term complications of the disease.